Physician profile
Susan E Jackson
NPI 1649557208
$7,057.81
in general payments reported to CMS, 2019-2025
23 companies · $2,962 in 2025
The $2,962 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $378 · 2023: $1,257 · 2024: $2,073 · 2025: $2,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,216 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,215.50 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,826.95 | 2021-2025 | |
| Janssen Biotech, INC. | $797.88 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $715.61 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $577.03 | 2024-2025 | |
| Ardelyx, INC. | $546.47 | 2023-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $380.37 | 2021-2023 | Fasenra, Breztri, Symbicort |
| Regeneron Healthcare Solutions, INC. | $337.50 | 2021-2025 | Dupixent |
| Madrigal Pharmaceuticals | $333.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Glaxosmithkline, LLC. | $269.12 | 2021-2023 | Nucala |
| Gilead Sciences, INC. | $253.50 | 2023-2025 | Epclusa |
| Phathom Pharmaceuticals, INC. | $177.01 | 2024-2025 | Voquezna |
| Silk Road Medical, INC. | $134.88 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.74 | 2021-2023 | Cyltezo, Ofev |
| Lilly USA, LLC | $98.05 | 2025 | Omvoh |
| Amgen INC. | $97.59 | 2022-2023 | Tezspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $90.37 | 2021-2025 | |
| Sandoz INC. | $81.08 | 2024-2025 | Hyrimoz |
| Novo Nordisk INC | $66.62 | 2025 | Wegovy |
| Mylan Specialty L.P. | $47.64 | 2022-2023 | Yupelri |
| Aimmune Therapeutics, INC. | $37.93 | 2025 | Vowst, Zenpep |
| Baxter Healthcare | $33.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.66 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.83 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.